Taysha Gene Therapies Files 2025 Annual Report
Ticker: TSHA · Form: ARS · Filed: Apr 22, 2026 · CIK: 0001806310
Sentiment: neutral
Topics: annual-report, sec-filing, gene-therapy
TL;DR
Taysha Gene Therapies filed its 2025 ARS. Check financials.
AI Summary
Taysha Gene Therapies, Inc. filed its Annual Report to Security Holders (ARS) on April 22, 2026, for the period ending December 31, 2025. The company is based in Dallas, Texas, and operates in the biological products sector. This filing provides a comprehensive overview of the company's performance and financial standing for the fiscal year 2025.
Why It Matters
This filing provides shareholders and potential investors with crucial information about Taysha Gene Therapies' financial health and operational performance for the fiscal year 2025.
Risk Assessment
Risk Level: medium — As a gene therapy company, Taysha Gene Therapies operates in a high-risk, high-reward sector with significant research and development costs and regulatory hurdles.
Key Numbers
- 2025 — Fiscal Year End (The period covered by the Annual Report to Security Holders.)
- 2026-04-22 — Filing Date (The date Taysha Gene Therapies, Inc. submitted its ARS filing.)
Key Players & Entities
- Taysha Gene Therapies, Inc. (company) — Filer of the ARS report
- 0001806310 (company) — CIK number for Taysha Gene Therapies, Inc.
- 2026-04-22 (date) — Filing date of the ARS report
- 2025-12-31 (date) — Period of report for the ARS filing
- 3000 PEGASUS PARK DRIVE SUITE 1430 DALLAS TX 75247 (address) — Mailing and Business Address for Taysha Gene Therapies, Inc.
FAQ
What is the CIK number for Taysha Gene Therapies, Inc.?
The CIK number for Taysha Gene Therapies, Inc. is 0001806310.
When was the Annual Report to Security Holders (ARS) filed?
The ARS was filed on April 22, 2026.
What period does this ARS filing cover?
This ARS filing covers the period ending December 31, 2025.
What is the business address of Taysha Gene Therapies, Inc.?
The business address is 3000 PEGASUS PARK DRIVE SUITE 1430 DALLAS TX 75247.
What is the SIC code for Taysha Gene Therapies, Inc.?
The SIC code is 2836, which pertains to Biological Products (No Diagnostic Substances).
Filing Details
This Form ARS (Form ARS) was filed with the SEC on April 22, 2026 regarding Taysha Gene Therapies, Inc. (TSHA).